Good morning, all. Damian here with news of a new biotech venture fund, a bold bet against a billion-dollar deal, and the weight of expectations on Eli Lilly.The need-to-know this morningBiotech earnings last night: Amgen and Gilead Sciences.BridgeBio Pharma granted Kyowa Kirin a license to co-develop an experimental drug, called infigratinib, for skeletal dysplasias in […]
